CD20 monoclonal antibody targeted nanoscale drug delivery system for doxorubicin chemotherapy: an in vitro study of cell lysis of CD20-positive Raji cells

References

• SunJYangQLuZDistribution of lymphoid neoplasms in China: analysis of 4,638 cases according to the World Health Organization classificationAm J Clin Pathol2012138342943422912361
   PubMed Web of Science ®Google Scholar
• CheahCYFowlerNHWangMLBreakthrough therapies in B-cell non-Hodgkin lymphomaAnn Oncol201627577878726802148
   PubMed Web of Science ®Google Scholar
• JudithJFelixBSusanneMHantelCSüssRLiposomal doxorubicin for active targeting: surface modification of the nanocarrier evaluated in vitro and in vivo challenges and prospectsOncotarget2015641436984371126497207
   PubMedGoogle Scholar
• ShettyRKAdamsBHTunHWRunyanBRMenkeDMBroderickDFUse of rituximab for periocular and intraocular mucosa-associated lymphoid tissue lymphomaOcul Immunol Inflamm201018211012220370339
   PubMed Web of Science ®Google Scholar
• EsmaeliBMcLaughlinPProBProspective trial of targeted radioimmunotherapy with Y-90 ibritumomab tiuxetan (Zevalin) for front-line treatment of early-stage extranodal indolent ocular adnexal lymphomaAnn Oncol200920470971419150940
   PubMed Web of Science ®Google Scholar
• TanCWaldmannTAProteasome inhibitor PS-341, a potential therapeutic agent for adult T-cell leukemiaCancer Res20026241083108611861386
   PubMedGoogle Scholar
• MurawskiNZwickCPfreundschuhMUnresolved issues in diffuse large B-cell lymphomasExpert Rev Anticancer Ther201010338740220214520
   PubMed Web of Science ®Google Scholar
• PiktelENiemirowiczKWątekMWollnyTDeptułaPBuckiRRecent insights in nanotechnology-based drugs and formulations designed for effective anti-cancer therapyJ Nanobiotechnology20161413927229857
   PubMed Web of Science ®Google Scholar
• BertrandNWuJXuXYKamalyNFarokhzadOCCancer Nanotechnology: the impact of passive and active targeting in the era of modern cancer biologyAdv Drug Deliv Rev20146622524270007
   PubMed Web of Science ®Google Scholar
• StylianopoulosTJainRKDesign considerations for nanotherapeutics in oncologyNanomedicine20151181893189026282377
   PubMed Web of Science ®Google Scholar
• YuMZhengJClearance Pathways and Tumor Targeting of Imaging NanoparticlesACS Nano2015976655667426149184
   PubMed Web of Science ®Google Scholar
• CerqueiraBBLashamAShellingANAl-KassasRNanoparticle therapeutics: technologies and methods for overcoming cancerEur J Pharm Biopharm201597Pt A14015126515260
   PubMedGoogle Scholar
• FangJNakamuraHMaedaHThe EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effectAdv Drug Deliv Rev201163313615120441782
   PubMed Web of Science ®Google Scholar
• TaurinSNehoffHGreishKAnticancer nanomedicine and tumor vascular permeability: Where is the missing link?J Control Release2012164326527522800576
   PubMed Web of Science ®Google Scholar
• MaedaHVascular permeability in cancer and infection as related to macromolecular drug delivery, with emphasis on the EPR effect for tumor-selective drug targetingProc Jpn Acad Ser B Phys Biol Sci20128835371
   PubMed Web of Science ®Google Scholar
• YokotaTSaitoTNarushimaYLympha-node staining with activated carbon CH40: a new method for axillary lymph-node dissection in breast cancerCan J Surg200043319119610851412
   PubMedGoogle Scholar
• NakaseYHagiwaraAKinSIntratumoral administration of methotrexate bound to activated carbon partieles: antitumor effectiveness against human colon carcinoma xenografts and acute toxicity in miceJ Pharmacol Exp Ther2004311138238715175420
   PubMedGoogle Scholar
• HagiwaraAToriiTSawaiKLocal injection of anti-cancer drugs bound to carbon particles for early gastric cancer – a pilot studyHepatogastroenterology2000473257557810791242
   PubMedGoogle Scholar
• ZhongYShuzhengMYinggeZUsing activated carbon nanoparticles to decrease the genotoxicity and teratogenicity of anticancer therapeutic agentsJ Nanosci Nanotechnol201010128603860921121372
   PubMed Web of Science ®Google Scholar
• ZhaoBSunLZhangWSecretion of intestinal goblet cells: a novel excretion pathway of nanoparticlesNanomedicine201410483984924183999
   PubMedGoogle Scholar
• LiuZhRobinsonJTSunXMDaiHJPEGylated nanographene oxide for delivery of water insoluble cancer drugsJ Am Chem Soc200813033108761087718661992
   PubMed Web of Science ®Google Scholar
• SahuAChoiWILeeJHTaeGGraphene oxide mediated delivery of methylene blue for combined photodynamic and photothermal therapyBiomaterials201334266239624823706688
   PubMed Web of Science ®Google Scholar
• ShenHZhangLLiuMZhangZBiomedical applications of grapheneTheranostics20122328329422448195
   PubMed Web of Science ®Google Scholar
• QuQLZhangYGSunLAdsorption and sustained release of mitomycin C by activated carbon nano-particlesBull Acad Mil Med Sci2004286551552
   Google Scholar
• QuQLZhangYGYangLZSunLIntraperitoneal chemotherapy with mitomycin C bound to activated carbon particles for nude mice bearing human gastric carcinomaChin J Oncol2006284257261
   Google Scholar
• SunLZhangYGYangLZObservation of the lymph tissue-targeting property, retention in the intraperitoneal activated carbon nano-particles in miceBull Acad Mil Med Sci2005294349351
   Google Scholar
• YangLZSunLZhangYGDistribution, migration and excretion of bio-inert nano-particles in vivoLett Biotechnol2005165525527
   Google Scholar
• ZhangHSunLXiaoEQuQLJiangSZhangYGIntraperitoneal chemotherapy with mitomycin C bound to activated carbon nano-particles using bioluminescence imaging technologyMil Med Sci2011354299303
   Google Scholar
• YangLZZhangYGPharmacokinetic study of intraperitoneal chemotherapy with mitomycin C absorbed to activated carbon particles in ratsJ Cancer Prev Treat2008152015481551
   Google Scholar
• MezzarobaNZorzetSSeccoENew potential therapeutic approach for the treatment of B-cell malignancies using chlorambucil/hydroxychloroquine-loaded anti-CD20 nanoparticlesPlos One201389e7421624098639
   PubMed Web of Science ®Google Scholar
• ZhuXWuJShanWPolymeric nanoparticles a menable to simultaneous installation of exterior targeting and interior therapeutic proteinsAngew Chem Int Ed Engl201655103309331226846161
   PubMedGoogle Scholar
• LiYYuanJNYangQImmunoliposome co-delivery of bufalin and anti-CD40 antibody adjuvant induces synergetic therapeutic efficacy against melanomaInt J Nanomed2014956835700
   PubMed Web of Science ®Google Scholar
• YaoHJZhangYGSunLLiuYThe effect of hyaluronic acid functionalized carbon nanotubes loaded with salinomycin on gastric cancer stem cellsBiomaterials2015353392089223
   Google Scholar
• YaoHJSunLLiuYMonodistearoylphosphatidylethanolamine-hyaluronic acid functionalization of single-walled carbon nanotubes for targeting intracellular drug delivery to overcome multidrug resistance of cancer cellsCarbon201696362376
   Web of Science ®Google Scholar
• RoskopfCCBraciakTAFennNCDual-targeting triplebody 33-3-19 mediates selective lysis of biphenotypic CD19+ CD33+ leukemia cellsOncotarget2016716225792258926981773
   PubMedGoogle Scholar
• YingXWenHLuWLDual-targeting daunorubicin liposomes improve the therapeutic efficacy of brain glioma in animalsJ Control Release2010141218319219799948
   PubMed Web of Science ®Google Scholar